

*Coming in May...*

## CME-Accredited Roundtable Monograph Supplement

An expert review of clinical challenges in psychiatry and neurology

### The Differential Diagnosis of Pseudobulbar Affect *Distinguishing PBA from Disorders of Mood and Affect*

**Moderators:** David Arciniegas, MD, and Edward Lauterbach, MD

**Participants:** Karen Anderson, MD, Tiffany Chow, MD, Laura Flashman, PhD, Daniel Kaufer, MD, Thomas McAllister, MD, Alya Reeve, MD, Robin Hurley, MD, John Silver, MD, and Randolph Schiffer, MD

Supported through an unrestricted educational grant by Avanir

The Tuscany School of Psychiatry and Clinical Neurosciences Presents  
its 2nd Course "The Neuroscience of Affective Disorder Spectrum"

*July 23, 2005 through August 5, 2005 in Florence, Italy*

Topics for the 2nd Course include:

- Treatment of Resistant Affective Disorders
- Psychometric Assessments
- Comprehensive Approaches
- Clinical Case Workshops
- Discussion on New Treatments

Faculty: Eric Hollander, MD, New York, USA; Lorrin Koran, MD, California, USA;  
Stefano Pallanti, MD, Florence, Italy; and Joseph Zohar, MD, Tel-Hashomer, Israel



There will be CME Credits available for participating physicians

For more information and to register for the event,  
please visit [www.tspcn.it](http://www.tspcn.it) or e-mail [info@tspcn.it](mailto:info@tspcn.it)

Join MBL  
Communications,  
Inc. at the 158th  
Annual Meeting  
of the American  
Psychiatric  
Association

Atlanta, Georgia

- A complimentary iPod to one lucky winner
- 2005 Editorial Award Winners will be announced

Please visit us at  
Booth #1004

Meeting Dates:  
May 21–26

Exhibit Dates:  
May 22–25

CONGRATULATIONS  
TO THE ADAA  
ON 25 YEARS  
OF DEDICATED  
SERVICE IN  
ANXIETY  
DISORDERS  
RESEARCH AND  
AWARENESS

MBL Communications, publisher of *PRIMARY PSYCHIATRY* and *CNS SPECTRUMS*, congratulates the entire staff of the ADAA on providing 25 years of superior education to physicians and patients on recognition and treatment of anxiety disorders. MBL is pleased to congratulate the ADAA Research Recognition Awards Winners:

- Philip C. Kendall, PhD, ABPP, from Temple University for Excellence in Anxiety Disorders in Children and Teens
- Barbara O. Rothbaum, PhD, from Emory University, for General Research in Anxiety Disorders

**MBL**  
communications



**PRIMARY PSYCHIATRY**  
The Leading Voice of Clinical Psychiatric Medicine

**CNS SPECTRUMS**  
The International Journal of Neuropsychiatric Medicine

# RISPERDAL® (RISPERIDONE) TABLETS/ORAL SOLUTION

# RISPERDAL® M-TAB® (RISPERIDONE) ORALLY DISINTEGRATING TABLETS

BEFORE PRESCRIBING, PLEASE CONSULT COMPLETE PRESCRIBING INFORMATION OF WHICH THE FOLLOWING IS A BRIEF SUMMARY.

## INDICATIONS AND USAGE

RISPERDAL® (risperidone) is indicated for the treatment of schizophrenia.

**Monotherapy:** RISPERDAL® is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder.

**Combination Therapy:** The combination of RISPERDAL® with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder.

## CONTRAINDICATIONS

RISPERDAL® (risperidone) is contraindicated in patients with a known hypersensitivity to the product.

## WARNINGS

**Neuroleptic Malignant Syndrome (NMS)** A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.

**Tardive Dyskinesia** A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. If signs and symptoms of tardive dyskinesia appear in a patient on RISPERDAL®, drug discontinuation should be considered. However, some patients may require treatment with RISPERDAL® despite the presence of the syndrome.

**Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients With Dementia** Cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients (mean age 85 years; range 73-97) in trials of risperidone in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with risperidone compared to patients treated with placebo. RISPERDAL® has not been shown to be safe or effective in the treatment of patients with dementia-related psychosis.

**Hyperglycemia and Diabetes Mellitus** Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including RISPERDAL®. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment.

## PRECAUTIONS

### General

**Orthostatic Hypotension:** RISPERDAL® (risperidone) may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period, probably reflecting its alpha-adrenergic antagonistic properties. Syncope was reported in 0.2% (6/2607) of RISPERDAL® treated patients in phase 2-3 studies. The risk of orthostatic hypotension and syncope may be minimized by limiting the initial dose to 2 mg total (either QD or 1 mg BID) in normal adults and 0.5 mg BID in the elderly and patients with renal or hepatic impairment (See DOSAGE AND ADMINISTRATION). Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern. A dose reduction should be considered if hypotension occurs. RISPERDAL® should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension e.g., dehydration and hypovolemia. Clinically significant hypotension has been observed with concomitant use of RISPERDAL® and antihypertensive medication.

**Seizures:** RISPERDAL® should be used cautiously in patients with a history of seizures.

**Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's dementia. RISPERDAL® and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

**Osteodystrophy and Tumors in Animals:** RISPERDAL® CONSTA™ produced osteodystrophy in male and female rats in a 1-year toxicity study and a 2-year carcinogenicity study at a dose of 40 mg/kg administered IM every 2 weeks. RISPERDAL® CONSTA™ produced renal tubular tumors (adenoma, adenocarcinoma) and adrenomedullary pheochromocytomas in male rats in the 2-year carcinogenicity study at 40 mg/kg administered IM every 2 weeks. In addition, RISPERDAL® CONSTA™ produced an increase in a marker of cellular proliferation in renal tissue in males in the 1-year toxicity study and in renal tumor-bearing males in the 2-year carcinogenicity study at 40 mg/kg administered IM every 2 weeks.

**Hyperprolactinemia:** As with other drugs that antagonize dopamine D<sub>2</sub> receptors, risperidone elevates prolactin levels and the elevation persists during chronic administration. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time.

**Potential for Cognitive and Motor Impairment:** Somnolence was a commonly reported adverse event associated with RISPERDAL® treatment, especially when ascertained by direct questioning of patients. This adverse event is dose related. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that RISPERDAL® therapy does not affect them adversely.

**Priapism:** Rare cases of priapism have been reported.

**Thrombotic Thrombocytopenic Purpura (TTP):** A single case of TTP was reported in a 28-year-old female patient receiving RISPERDAL® in a large, open premarketing experience (approximately 1300 patients). She experienced jaundice, fever, and bruising, but eventually recovered after receiving plasmapheresis. The relationship to RISPERDAL® therapy is unknown.

**Antiemetic Effect:** Risperidone has an antiemetic effect in animals; this effect may also occur in humans, and may mask signs and symptoms of overdose with certain drugs or of conditions such as intestinal obstruction, Reye's syndrome, and brain tumor.

**Body Temperature Regulation:** Disruption of body temperature regulation has been attributed to antipsychotic agents. Caution is advised when prescribing for patients who will be exposed to temperature extremes.

**Suicide:** The possibility of a suicide attempt is inherent in schizophrenia, and close supervision of high risk patients should accompany drug therapy.

**Use in Patients With Concomitant Illness:** Clinical experience with RISPERDAL® in patients with certain concomitant systemic illnesses is limited. Patients with Parkinson's Disease or Dementia with Lewy Bodies who receive antipsychotics may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotic medications. Manifestation of this increased sensitivity can include confusion, obtundation, postural instability with frequent falls, in addition to extrapyramidal symptoms. Caution is advisable in using RISPERDAL® in patients with diseases or conditions that could affect metabolism or hemodynamic responses.

Because of the risks of orthostatic hypotension and QT prolongation, caution should be observed in cardiac patients (see WARNINGS and PRECAUTIONS).

Increased plasma concentrations of risperidone and 9-hydroxyrisperidone occur in patients with severe renal impairment and in patients with severe hepatic impairment. A lower starting dose should be used in such patients.

**Information for Patients** Physicians are advised to consult full prescribing information to review issues to be discussed with patients for whom they prescribe RISPERDAL®.

**Phenylethanolamines** Phenylalanine is a component of aspartame. Each 2 mg RISPERDAL® M-TAB™ Orally Disintegrating Tablet contains 0.56 mg phenylalanine; each 1 mg RISPERDAL® M-TAB™ Orally Disintegrating Tablet contains 0.28 mg phenylalanine; and each 0.5 mg RISPERDAL® M-TAB™ Orally Disintegrating Tablet contains 0.14 mg phenylalanine.

**Drug Interactions:** The interactions of RISPERDAL® and other drugs have not been systematically evaluated. Given the primary CNS effects of risperidone, caution should be used when RISPERDAL® is taken in combination with other centrally acting drugs and alcohol. Because of its potential for inducing hypotension, RISPERDAL® may enhance the hypotensive effects of other therapeutic agents with this potential. RISPERDAL® may antagonize the effects of levodopa and dopamine agonists. Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.

**Carbamazepine and Other Enzyme Inducers:** In a drug interaction study in schizophrenic patients, 11 subjects received risperidone titrated to 6 mg/day for 3 weeks, followed by concurrent administration of carbamazepine for an additional 3 weeks. During co-administration, the plasma concentrations of risperidone and its pharmacologically active metabolite, 9-hydroxyrisperidone, were decreased by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy. Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.

**Fuoxetine:** Fluoxetine (20 mg QD) has been shown to increase the plasma concentration of risperidone 2.5-2.8 fold, while the plasma concentration of 9-hydroxyrisperidone was not affected. When concomitant fluoxetine is initiated or discontinued, the physician should re-evaluate the dosing of RISPERDAL®. The effects of discontinuation of concomitant fluoxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.

**Lithium:** Repeated oral doses of risperidone (3 mg BID) did not affect the exposure (AUC) or peak plasma concentrations (C<sub>max</sub>) of lithium (n=13).

**Valproate:** Repeated oral doses of risperidone (4 mg QD) did not affect the pre-dose or average plasma concentrations

exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (C<sub>max</sub>) after concomitant administration of risperidone.

**Drugs that Inhibit CYP 2D6 and Other CYP Isozymes:** Risperidone is metabolized to 9-hydroxyrisperidone by cytochrome P<sub>450</sub>2D<sub>6</sub>, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs (see CLINICAL PHARMACOLOGY). Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone. Analysis of clinical studies involving a modest number of poor metabolizers (n=70) does not suggest that poor and extensive metabolizers have different rates of adverse effects. No comparison of effectiveness in the two groups has been made. In vitro studies showed that drugs metabolized by other P<sub>450</sub> isozymes, including 1A1, 1A2, 1C9, 1P, and 1IA4, are only weak inhibitors of risperidone metabolism.

**Drugs Metabolized by CYP 2D6:** In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6. Therefore, RISPERDAL® is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. However, clinical data to confirm this expectation are not available.

**Carcinogenesis, Mutagenesis, Impairment of Fertility** **Carcinogenesis:** Carcinogenicity studies were conducted in Swiss albino mice and Wistar rats. Risperidone was administered in the diet at doses of 0.63, 2.5, and 10 mg/kg for 18 months to mice and for 25 months to rats. These doses are equivalent to 2.4, 9.4 and 37.5 times the maximum human dose (16 mg/day) on a mg/kg basis or 0.2, 0.75 and 3 times the maximum human dose (mice) or 0.4, 1.5, and 6 times the maximum human dose (rats) on a mg/m<sup>2</sup> basis. There were statistically significant increases in pituitary gland adenomas, endocrine pancreas adenomas and mammary gland adenocarcinomas. These findings are considered to be prolactin mediated. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (See Hyperprolactinemia under PRECAUTIONS, GENERAL).

**Mutagenesis:** No evidence of mutagenic potential for risperidone was found.

**Impairment of Fertility:** Risperidone (0.16 to 5 mg/kg) was shown to impair mating, but not fertility, in Wistar rats in three reproductive studies at doses 0.1 to 3 times the maximum recommended human dose on a mg/m<sup>2</sup> basis.

### Pregnancy Category C

The teratogenic potential of risperidone was studied in three Segment II studies in Sprague-Dawley and Wistar rats (0.63-10 mg/kg or 0.4 to 6 times the maximum recommended human dose [MRHD] on a mg/m<sup>2</sup> basis) and in one Segment II study in New Zealand rabbits (0.31-5 mg/kg or 0.4 to 6 times the MRHD on a mg/m<sup>2</sup> basis). The incidence of malformations was not increased compared to control in offspring of rats or rabbits given 0.4 to 6 times the MRHD on a mg/m<sup>2</sup> basis. In three reproductive studies in rats (two Segment III and a multigenerational study), there was an increase in pup deaths during the first 4 days of lactation at doses of 0.16-5 mg/kg or 0.1 to 3 times the MRHD on a mg/m<sup>2</sup> basis. It is not known whether these deaths were due to a direct effect on the fetuses or pups or to effects on the dams. There was no no-effect dose for increased rat pup mortality. In one Segment III study, there was an increase in stillborn rat pups at a dose of 2.5 mg/kg or 1.5 times the MRHD on a mg/m<sup>2</sup> basis. In a cross-fostering study in Wistar rats, toxic effects on the fetus or pups, as evidenced by a decrease in the number of live pups and an increase in the number of dead pups at birth (Day 0), and a decrease in birth weight in pups of drug-treated dams were observed. In addition, there was an increase in deaths by Day 1 among pups of drug-treated dams, regardless of whether or not the pups were cross-fostered. Risperidone also appeared to impair maternal behavior in that pup body weight gain and survival (from Day 1 to 4 of lactation) were reduced in pups born to control but reared by drug-treated dams. These effects were all noted at the one dose of risperidone tested, i.e., 5 mg/kg or 3 times the MRHD on a mg/m<sup>2</sup> basis. Placental transfer of risperidone occurs in rat pups. There are no adequate and well-controlled studies in pregnant women. However, there was one report of a case of agenesis of the corpus callosum in an infant exposed to risperidone *in utero*. The causal relationship to RISPERDAL® therapy is unknown. RISPERDAL® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Labor and Delivery** The effect of RISPERDAL® on labor and delivery in humans is unknown. **Nursing Mothers** In animal studies, risperidone and 9-hydroxyrisperidone are excreted in milk. Risperidone and 9-hydroxyrisperidone are also excreted in human breast milk. Therefore, women receiving risperidone should not breast-feed.

**Pediatric Use** Safety and effectiveness in children have not been established.

**Geriatric Use** Clinical studies of RISPERDAL® in the treatment of schizophrenia did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, a lower starting dose is recommended for an elderly patient, reflecting a decreased pharmacokinetic clearance in the elderly, as well as a greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION). While elderly patients exhibit a greater tendency to orthostatic hypotension, its risk in the elderly may be minimized by limiting the initial dose to 0.5 mg BID followed by careful titration (see PRECAUTIONS). Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION).

**Concomitant use with Furosemide in Elderly Patients with Dementia** In placebo-controlled trials in elderly patients with dementia-related psychosis, a higher incidence of mortality was observed in patients treated with furosemide plus oral risperidone (7.3%; mean age 89 years, range 75-97) when compared to patients treated with oral risperidone alone (3.1%; mean age 84 years, range 70-96) or furosemide alone (4.1%; mean age 80 years, range 67-90). The increase in mortality in patients treated with furosemide plus oral risperidone was observed in two of the four clinical trials.

No pathophysiologic mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed. Nevertheless, caution should be exercised and the risks and benefits of this combination should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant medication with risperidone. Irrespective of treatment, dehydration was an overall risk factor for mortality and should therefore be carefully avoided in elderly patients with dementia-related psychosis. RISPERDAL® CONSTA® is not approved for the treatment of patients with dementia-related psychosis.

## ADVERSE REACTIONS

### Associated With Discontinuation of Treatment

**Bipolar Mania** In the US placebo-controlled trial with risperidone as monotherapy, approximately 8% (10/134) of RISPERDAL®-treated patients discontinued treatment due to an adverse event, compared with approximately 6% (7/125) of placebo-treated patients. The adverse events associated with discontinuation and considered to be possibly, probably, or very likely drug-related included paranoia, somnolence, dizziness, extrapyramidal disorder, and muscle contractions involuntary. Each of these events occurred in one RISPERDAL®-treated patient (0.7%) and in no placebo-treated patients (0%).

In the US placebo-controlled trial with risperidone as adjunctive therapy to mood stabilizers, there was no overall difference in the incidence of discontinuation due to adverse events (4% for RISPERDAL® vs. 4% for placebo).

### Incidence in Controlled Trials Commonly Observed Adverse Events in Controlled Clinical Trials:

**Bipolar Mania:** In the US placebo-controlled trial with risperidone as monotherapy, the most commonly observed adverse events associated with the use of RISPERDAL® (incidence of 5% or greater and at least twice that of placebo) were somnolence, dystonia, akathisia, dyspepsia, nausea, parkinsonism, vision abnormal, and saliva increased. In the US placebo-controlled trial with risperidone as adjunctive therapy to mood stabilizers, the most commonly observed adverse events associated with the use of RISPERDAL® were somnolence, dizziness, parkinsonism, saliva increased, akathisia, abdominal pain, and urinary incontinence.

### Adverse Events Occurring at an Incidence of 2% or More Among RISPERDAL®-Treated Patients - Bipolar Mania

Adverse events that occurred at an incidence of 2% or more, and were more frequent among patients treated with flexible doses of RISPERDAL® (1-6 mg daily as monotherapy and as adjunctive therapy to mood stabilizers, respectively) than among patients treated with placebo. Reported adverse events were classified using the World Health Organization preferred terms. **Incidence of Treatment-Emergent Adverse Events in a 3-Week, Placebo-Controlled Trial (Monotherapy in Bipolar Mania)**

### Body System/Preferred Term

**Central & peripheral nervous system:** Dystonia, Akathisia, Dizziness, Parkinsonism, Hypoaesthesia **Psychiatric:** Somnolence, Agitation, Manic reaction, Anxiety, Concentration impaired **Gastrointestinal system:** Dyspepsia, Nausea, Saliva increased, Mouth dry **Body as a whole - general:** Pain, Fatigue, Injury **Respiratory system:** Sinusitis, Rhinitis, Coughing **Skin and appendage:** Acne, Pruritus **Musculo-Skeletal:** Myalgia, Skeletal pain **Metabolic and nutritional:** Weight increase **Vision disorders:** Vision abnormal **Cardiovascular, general:** Hypertension, Hypotension **Heart rate and rhythm:** Tachycardia

**Incidence of Treatment-Emergent Adverse Events in a 3-Week, Placebo-Controlled Trial (Adjunctive Therapy in Bipolar Mania)**

### Body System/Preferred Term

**Gastrointestinal system:** Saliva increased, Diarrhea, Abdominal pain, Constipation, Mouth dry, Tooth ache, Tooth disorder **Central & peripheral nervous system:** Dizziness, Parkinsonism, Akathisia, Dystonia **Psychiatric:** Somnolence, Anxiety, Confusion **Respiratory system:** Rhinitis, Pharyngitis, Coughing **Body as a whole - general:** Asthenia **Urinary system:** Urinary incontinence **Heart rate and rhythm:** Tachycardia **Metabolic and nutritional:** Weight increase **Skin and appendages:** Rash

### Dose Dependency of Adverse Events:

Data from two fixed dose trials provided evidence of dose-relatedness for extrapyramidal symptoms associated with risperidone treatment. These symptoms included: sleepiness, increased duration of sleep, accommodation disturbances, orthostatic dizziness, palpitations, weight gain, erectile dysfunction, ejaculatory dysfunction, organic dysfunction, asthenia/lassitude/increased fatigability, and increased pigmentation. **Vital Sign Changes:** RISPERDAL® is associated with

orthostatic hypotension and tachycardia (see PRECAUTIONS). **Weight Changes:** A statistically significantly greater incidence of weight gain for RISPERDAL® (18%) compared to placebo (9%).

**Laboratory Changes:** A between group comparison for 6- to 8-week placebo-controlled trials revealed no statistically significant RISPERDAL®/placebo differences in the proportions of patients experiencing potentially important changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no RISPERDAL®/placebo differences in the incidence of discontinuations for changes in serum chemistry, hematology, or urinalysis. However, RISPERDAL® administration was associated with increases in serum prolactin (see PRECAUTIONS).

**ECG Changes:** Between-group comparisons for pooled placebo-controlled trials revealed no statistically significant differences between risperidone and placebo in mean changes from baseline in ECG parameters, including QT, QTc, and PR intervals, and heart rate. When all RISPERDAL® doses were pooled from randomized controlled trials in several indications, there was a mean increase in heart rate of 1 beat per minute compared to no change for placebo patients. In short-term schizophrenia trials, higher doses of risperidone (8-16 mg/day) were associated with a higher mean increase in heart rate compared to placebo (4-6 beats per minute).

#### Other Events Observed During the Pre-Marketing Evaluation

During its premarketing assessment, multiple doses of RISPERDAL® (risperidone) were administered to 2607 patients in phase 2 and 3 studies and the following reactions were reported: (Note: frequent adverse events are those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. It is important to emphasize that, although the events reported occurred during treatment with RISPERDAL®, they were not necessarily caused by it.) **Psychiatric Disorders:** *Frequent:* increased dream activity\*, diminished sexual desire\*, nervousness. *Infrequent:* impaired concentration, depression, apathy, catatonic reaction, euphoria, increased libido, amnesia. *Rare:* emotional lability, nightmares, delirium, withdrawal syndrome, yawning. **Central and Peripheral Nervous System Disorder:** *Frequent:* increased sleep duration\*. *Infrequent:* dysarthria, vertigo, stupor, paraesthesia, confusion. *Rare:* aphasia, cholinergic syndrome, hypoesthesia, tongue paralysis, leg cramps, torticollis, hypotonia, coma, migraine, hyperreflexia, choreoathetosis. **Gastro-intestinal Disorders:** *Frequent:* anorexia, reduced salivation\*. *Infrequent:* flatulence, diarrhea, increased appetite, stomatitis, melena, dysphagia, hemorrhoids, gastritis. *Rare:* fecal incontinence, eructation, gastroesophageal reflux, gastroenteritis, esophagitis, tongue discoloration, cholelithiasis, tongue edema, diverticulitis, gingivitis, discolored feces, GI hemorrhage, hematemesis. **Body as a Whole/General Disorders:** *Frequent:* fatigue. *Infrequent:* edema, rigors, malaise, influenza-like symptoms. *Rare:* pallor, enlarged abdomen, allergic reaction, ascites, sarcoidosis, flushing. **Respiratory System Disorders:** *Infrequent:* hyperventilation, bronchospasm, pneumonia, stridor. *Rare:* asthma, increased sputum, aspiration. **Skin and Appendage Disorders:** *Frequent:* increased pigmentation\*, photosensitivity\*. *Infrequent:* increased sweating, acne, decreased sweating, alopecia, hyperkeratosis, pruritus, skin exfoliation. *Rare:* bullous eruption, skin ulceration, aggravated psoriasis, furunculosis, verruca, dermatitis lichenoid, hypertrichosis, genital pruritus, urticaria. **Cardiovascular Disorders:** *Infrequent:* palpitation, hypertension, hypotension, AV block, myocardial infarction. *Rare:* ventricular tachycardia, angina pectoris, premature atrial contractions, T wave inversions, ventricular extrasystoles, ST depression, myocarditis. **Vision Disorders:** *Infrequent:* abnormal accommodation, xerophthalmia. *Rare:* diplopia, eye pain, blepharitis, photopsia, photophobia, abnormal lacrimation. **Metabolic and Nutritional Disorders:** *Infrequent:* hyponatremia, weight increase, creatine phosphokinase increase, thirst, weight decrease, diabetes mellitus. *Rare:* decreased serum iron, cachexia, dehydration, hypokalemia, hypoproteinemia, hyperphosphatemia, hypertriglyceridemia, hyperuricemia, hypoglycemia. **Urinary System Disorders:** *Frequent:* polyuria/polydipsia\*. *Infrequent:* urinary incontinence, hematuria, dysuria. *Rare:* urinary retention, cystitis, renal insufficiency. **Musculo-skeletal System Disorders:** *Infrequent:* myalgia. *Rare:* arthrosis, synostosis, bursitis, arthritis, skeletal pain. **Reproductive Disorders, Female:** *Frequent:* menorrhagia\*, orgasmic dysfunction\*, dry vagina\*. *Infrequent:* nonpuerperal lactation, amenorrhea, female breast pain, leukorrhea, mastitis, dysmenorrhea, female perineal pain, intermenstrual bleeding, vaginal hemorrhage. **Liver and Biliary System Disorders:** *Infrequent:* increased SGOT, increased SGPT. *Rare:* hepatic failure, cholestatic hepatitis, cholecystitis, cholelithiasis, hepatitis, hepatocellular damage. **Platelet, Bleeding and Clotting Disorders:** *Infrequent:* epistaxis, purpura. *Rare:* hemorrhage, superficial phlebitis, thrombophlebitis, thrombocytopenia. **Hearing and Vestibular Disorders:** *Rare:* tinnitus, hyperacusis, decreased hearing. **Red Blood Cell Disorders:** *Infrequent:* anemia, hypochromic anemia. *Rare:* normocytic anemia. **Reproductive Disorders, Male:** *Frequent:* erectile dysfunction\*. *Infrequent:* ejaculation failure. **White Cell and Resistance Disorders:** *Rare:* leukocytosis, lymphadenopathy, leucopenia, Pelger-Huet anomaly. **Endocrine Disorders:** *Rare:* gynaecomastia, male breast pain, antidiuretic hormone disorder. **Special Sense:** *Rare:* bitter taste. **Postintroduction Reports:** Adverse events reported since market introduction which were temporally (but not necessarily causally) related to RISPERDAL® therapy, include the following: anaphylactic reaction, angioedema, apnea, atrial fibrillation, cerebrovascular disorder, including cerebrovascular accident, hyperglycemia, diabetes mellitus aggravated, including diabetic ketoacidosis, intestinal obstruction, jaundice, mania, pancreatitis, Parkinson's disease aggravated, pulmonary embolism. There have been rare reports of sudden death and/or cardiopulmonary arrest in patients receiving RISPERDAL®. A causal relationship with RISPERDAL® has not been established. It is important to note that sudden and unexpected death may occur in psychotic patients whether they remain untreated or whether they are treated with other antipsychotic drugs.

#### DRUG ABUSE AND DEPENDENCE

**Controlled Substance Class:** RISPERDAL® (risperidone) is not a controlled substance.

For information on symptoms and treatment of overdose, see full prescribing information.


More detailed professional information is available upon request.

© Janssen 2003 US Patent 4,804,663 Revised February 2005 7503228B

**JANSSEN**  **PHARMACEUTICA  
PRODUCTS, L.P.**

Titusville, NJ 08560

For many patients with bipolar mania  
In acute manic or mixed  
episodes of bipolar I disorder



Focused.  
Calm.  
Engaged.  
Stabilized.  
Risperdal.\*<sup>†</sup>

**Commonly observed events** associated with RISPERDAL at an incidence of  $\geq 5\%$  and at least  $2\times$  placebo: As monotherapy—somnolence, dystonia, akathisia, dyspepsia, nausea, parkinsonism, abnormal vision, saliva increase, and myalgia. As adjunctive therapy with mood stabilizers (lithium or valproate)—somnolence, dizziness, parkinsonism, saliva increase, akathisia, abdominal pain, urinary incontinence, diarrhea, and rhinitis.

**Hyperglycemia and diabetes:** Hyperglycemia, some cases extreme and associated with ketoacidosis, hyperosmolar coma or death has been reported in patients treated with atypical antipsychotics (APS), including RISPERDAL. Patients starting treatment with APS who have or are at risk for diabetes, should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

**Tardive dyskinesia:** As with all antipsychotic medications, prescribing should be consistent with the need to minimize the risk of tardive dyskinesia; if its signs and symptoms appear, discontinuation of RISPERDAL should be considered. Elderly patients appeared to be at increased risk for tardive dyskinesia.

**Neuroleptic malignant syndrome (NMS)** has been reported rarely with this class of medications, including RISPERDAL and appropriate management should be employed.

**Cerebrovascular adverse events (CAEs):** Cerebrovascular adverse events, including fatalities, have been reported in elderly patients with dementia-related psychosis taking risperidone in clinical trials. The incidence of CAEs with risperidone was significantly higher than with placebo. RISPERDAL, as with other atypicals, is not approved for treating these patients.

**Visit our Web site at [risperdal.com](http://risperdal.com)**

\*All items of the Young Mania Rating Scale (YMRS) improved significantly except for appearance.

**Reference: 1.** Data on file: RIS-USA-239 Study (a double-blind, placebo-controlled monotherapy trial), Janssen Pharmaceutica Products, L.P., Titusville, NJ.

Please see brief summary of full Prescribing Information on adjacent page.

JANSSEN



PHARMACEUTICA  
PRODUCTS, L.P.



© Janssen 2005 01-RS-1603 Printed in U.S.A. February 2005

**Risperdal**  
tablets and  
oral solution 1 mg/mL  
RISPERIDONE



Helping Turn Lives Around